Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation : Ototoxicity following tobramycin treatment
Copyright © 2020. Published by Elsevier B.V..
Aminoglycosides are commonly used to treat infections in CF patients and are highly ototoxic. The incidence of tobramycin-induced hearing loss, tinnitus, vertigo or dizziness (ototoxicity) varies widely from 0 to 56% secondary to variation in patient enrollment, dosing, audiometry, and ototoxic criteria. The aim of this study is to determine the incidence of ototoxicity after one course of once-daily IV tobramycin in CF patients. Adult CF patients with acute pulmonary exacerbations were enrolled on IV tobramycin (10 mg/kg/d, ≥10 days). Pure-tone audiometry was performed for standard and extended high frequencies in the sensitive range for ototoxicity (SRO). American-Speech-Language-Hearing-Association cochleotoxicity criteria were applied. Distortion product otoacoustic emissions (DPOAE) and the words-in-noise-test (WINT) were assessed. Tinnitus Functional Index (TFI) and Vertigo Symptoms Scale (VSS) were used. Eighteen CF patients, mean age 31.1 (18-59), were enrolled. The incidence of cochleotoxic change from baseline at 2 and 4 weeks post-treatment was 89% and 93%. For DPOAE, a measure of outer hair-cell function, the incidence of ≥5 dB decrease was 82% and 80%. For WINT, a measure of word recognition, the incidence of ≥10% decrease was 17% and 40%. For TFI, the incidence of ≥10pt increase was 12% and 8%, and for VSS, the incidence of ≥6pt increase was 0% and 8%. One course of IV tobramycin was sufficient to cause hearing loss and other ototoxic symptoms four weeks after treatment ended. Audiometric measures were more sensitive to ototoxic change than TFI & VSS. Age and duration of tobramycin treatment were not obvious factors for predicting ototoxicity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 20(2021), 2 vom: 01. März, Seite 288-294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Harruff, E Emily [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aminoglycoside |
|---|
| Anmerkungen: |
Date Completed 21.01.2022 Date Revised 21.01.2022 published: Print-Electronic ClinicalTrials.gov: NCT02819856 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jcf.2020.11.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319062570 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319062570 | ||
| 003 | DE-627 | ||
| 005 | 20231225170647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcf.2020.11.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1063.xml |
| 035 | |a (DE-627)NLM319062570 | ||
| 035 | |a (NLM)33341407 | ||
| 035 | |a (PII)S1569-1993(20)30930-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Harruff, E Emily |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation |b Ototoxicity following tobramycin treatment |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.01.2022 | ||
| 500 | |a Date Revised 21.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02819856 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
| 520 | |a Aminoglycosides are commonly used to treat infections in CF patients and are highly ototoxic. The incidence of tobramycin-induced hearing loss, tinnitus, vertigo or dizziness (ototoxicity) varies widely from 0 to 56% secondary to variation in patient enrollment, dosing, audiometry, and ototoxic criteria. The aim of this study is to determine the incidence of ototoxicity after one course of once-daily IV tobramycin in CF patients. Adult CF patients with acute pulmonary exacerbations were enrolled on IV tobramycin (10 mg/kg/d, ≥10 days). Pure-tone audiometry was performed for standard and extended high frequencies in the sensitive range for ototoxicity (SRO). American-Speech-Language-Hearing-Association cochleotoxicity criteria were applied. Distortion product otoacoustic emissions (DPOAE) and the words-in-noise-test (WINT) were assessed. Tinnitus Functional Index (TFI) and Vertigo Symptoms Scale (VSS) were used. Eighteen CF patients, mean age 31.1 (18-59), were enrolled. The incidence of cochleotoxic change from baseline at 2 and 4 weeks post-treatment was 89% and 93%. For DPOAE, a measure of outer hair-cell function, the incidence of ≥5 dB decrease was 82% and 80%. For WINT, a measure of word recognition, the incidence of ≥10% decrease was 17% and 40%. For TFI, the incidence of ≥10pt increase was 12% and 8%, and for VSS, the incidence of ≥6pt increase was 0% and 8%. One course of IV tobramycin was sufficient to cause hearing loss and other ototoxic symptoms four weeks after treatment ended. Audiometric measures were more sensitive to ototoxic change than TFI & VSS. Age and duration of tobramycin treatment were not obvious factors for predicting ototoxicity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Aminoglycoside | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a Hearing loss | |
| 650 | 4 | |a Ototoxicity | |
| 650 | 4 | |a Tinnitus | |
| 650 | 4 | |a Tobramycin | |
| 650 | 7 | |a Aminoglycosides |2 NLM | |
| 650 | 7 | |a Tobramycin |2 NLM | |
| 650 | 7 | |a VZ8RRZ51VK |2 NLM | |
| 700 | 1 | |a Kil, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz, Maria Gabriela Tupayachi |e verfasserin |4 aut | |
| 700 | 1 | |a Dorgan, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Raksha |e verfasserin |4 aut | |
| 700 | 1 | |a Poth, Elizabeth A |e verfasserin |4 aut | |
| 700 | 1 | |a Fifer, Robert C |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Yun Jin M |e verfasserin |4 aut | |
| 700 | 1 | |a Shoup, Angela G |e verfasserin |4 aut | |
| 700 | 1 | |a Flume, Patrick A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society |d 2002 |g 20(2021), 2 vom: 01. März, Seite 288-294 |w (DE-627)NLM15136754X |x 1873-5010 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g number:2 |g day:01 |g month:03 |g pages:288-294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jcf.2020.11.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |e 2 |b 01 |c 03 |h 288-294 | ||